302 related articles for article (PubMed ID: 32001676)
1. Comprehensive T cell repertoire characterization of non-small cell lung cancer.
Reuben A; Zhang J; Chiou SH; Gittelman RM; Li J; Lee WC; Fujimoto J; Behrens C; Liu X; Wang F; Quek K; Wang C; Kheradmand F; Chen R; Chow CW; Lin H; Bernatchez C; Jalali A; Hu X; Wu CJ; Eterovic AK; Parra ER; Yusko E; Emerson R; Benzeno S; Vignali M; Wu X; Ye Y; Little LD; Gumbs C; Mao X; Song X; Tippen S; Thornton RL; Cascone T; Snyder A; Wargo JA; Herbst R; Swisher S; Kadara H; Moran C; Kalhor N; Zhang J; Scheet P; Vaporciyan AA; Sepesi B; Gibbons DL; Robins H; Hwu P; Heymach JV; Sharma P; Allison JP; Baladandayuthapani V; Lee JJ; Davis MM; Wistuba II; Futreal PA; Zhang J
Nat Commun; 2020 Jan; 11(1):603. PubMed ID: 32001676
[TBL] [Abstract][Full Text] [Related]
2. Detection of oligoclonal T lymphocytes in lymph nodes draining from advanced non-small-cell lung cancer.
Meta M; Ponte M; Guastella M; Semino C; Pietra G; Ratto GB; Melioli G
Cancer Immunol Immunother; 1995 Apr; 40(4):235-40. PubMed ID: 7750121
[TBL] [Abstract][Full Text] [Related]
3. Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape.
Xia W; Mao W; Chen R; Lu R; Liu F; He Y; Wang S; Li X; Zheng M
Med Sci Monit; 2019 Nov; 25():8764-8776. PubMed ID: 31746315
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
5. Immune Cell Composition in Human Non-small Cell Lung Cancer.
Stankovic B; Bjørhovde HAK; Skarshaug R; Aamodt H; Frafjord A; Müller E; Hammarström C; Beraki K; Bækkevold ES; Woldbæk PR; Helland Å; Brustugun OT; Øynebråten I; Corthay A
Front Immunol; 2018; 9():3101. PubMed ID: 30774636
[TBL] [Abstract][Full Text] [Related]
6. Antigen-Presenting Intratumoral B Cells Affect CD4
Bruno TC; Ebner PJ; Moore BL; Squalls OG; Waugh KA; Eruslanov EB; Singhal S; Mitchell JD; Franklin WA; Merrick DT; McCarter MD; Palmer BE; Kern JA; Slansky JE
Cancer Immunol Res; 2017 Oct; 5(10):898-907. PubMed ID: 28848053
[TBL] [Abstract][Full Text] [Related]
7. Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype.
Palata O; Podzimkova Hradilova N; Mysiková D; Kutna B; Mrazkova H; Lischke R; Spisek R; Adkins I
Immunol Lett; 2020 Mar; 219():46-53. PubMed ID: 31931024
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
9. The immune response-related mutational signatures and driver genes in non-small-cell lung cancer.
Chen H; Chong W; Teng C; Yao Y; Wang X; Li X
Cancer Sci; 2019 Aug; 110(8):2348-2356. PubMed ID: 31222843
[TBL] [Abstract][Full Text] [Related]
10. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer.
Jia Q; Wu W; Wang Y; Alexander PB; Sun C; Gong Z; Cheng JN; Sun H; Guan Y; Xia X; Yang L; Yi X; Wan YY; Wang H; He J; Futreal PA; Li QJ; Zhu B
Nat Commun; 2018 Dec; 9(1):5361. PubMed ID: 30560866
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of peripheral blood T lymphocyte surface activation markers and transcription factors in patients with early stage non-small cell lung cancer.
Rutkowski J; Cyman M; Ślebioda T; Bemben K; Rutkowska A; Gruchała M; Kmieć Z; Pliszka A; Zaucha R
Cell Immunol; 2017 Dec; 322():26-33. PubMed ID: 28939130
[TBL] [Abstract][Full Text] [Related]
12. Lung tissue and tumour-infiltrating T lymphocytes in patients with non-small cell lung carcinoma and chronic obstructive pulmonary disease (COPD): moderate/severe versus mild stage of COPD.
Marc MM; Korosec P; Kern I; Sok M; Ihan A; Kosnik M
Scand J Immunol; 2007 Dec; 66(6):694-702. PubMed ID: 17949407
[TBL] [Abstract][Full Text] [Related]
13. Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.
Markowitz GJ; Havel LS; Crowley MJ; Ban Y; Lee SB; Thalappillil JS; Narula N; Bhinder B; Elemento O; Wong ST; Gao D; Altorki NK; Mittal V
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997286
[TBL] [Abstract][Full Text] [Related]
14. Systemic Immune Dysregulation Correlates With Clinical Features of Early Non-Small Cell Lung Cancer.
Hao Z; Lin M; Du F; Xin Z; Wu D; Yu Q; Wu Y; Zhu Z; Li W; Chen Y; Chen X; Chai Y; Jin S; Wu P
Front Immunol; 2021; 12():754138. PubMed ID: 35116020
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
Qu J; Mei Q; Chen L; Zhou J
Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.
Usó M; Jantus-Lewintre E; Bremnes RM; Calabuig S; Blasco A; Pastor E; Borreda I; Molina-Pinelo S; Paz-Ares L; Guijarro R; Martorell M; Forteza J; Camps C; Sirera R
Oncotarget; 2016 Aug; 7(33):52849-52861. PubMed ID: 27463005
[TBL] [Abstract][Full Text] [Related]
17. HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
Cheng H; Janakiram M; Borczuk A; Lin J; Qiu W; Liu H; Chinai JM; Halmos B; Perez-Soler R; Zang X
Clin Cancer Res; 2017 Feb; 23(3):825-832. PubMed ID: 27553831
[TBL] [Abstract][Full Text] [Related]
18. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice.
Li H; Huang Y; Jiang DQ; Cui LZ; He Z; Wang C; Zhang ZW; Zhu HL; Ding YM; Li LF; Li Q; Jin HJ; Qian QJ
Cell Death Dis; 2018 Feb; 9(2):177. PubMed ID: 29415996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
